Neuronostics is a multi-award-winning start-up developing solutions for diagnosis and management of neurological conditions. Neuronostics technology uses advanced mathematical modelling and machine learning tools to create digital biomarkers that reveal the risk of neurological conditions from routinely acquired clinical data.
Spun out of the University of Exeter in 2018, its first focus is on epilepsy: a condition affecting 65 million globally. Epilepsy is hard to diagnose, easy to misdiagnose and difficult to treat. It takes a year on average to confirm a case. Misdiagnosis rates can exceed 30%. 50% of people with epilepsy are not seizure free a year post-treatment. Addressing these challenges Neuronostics’ patented BioEP marker reveals the risk of future seizures from just a few seconds of apparently normal EEG. Published studies have shown that BioEP matches current clinical practice. Recent work has shown that changes in the BioEP score over time reveals medication response.